Rayno Biopharma Portfolio Update: ALXN, BIIB, CBST,REGN, VPHM

Mar 30, 2012 | BIOgraph, Biopharmaceuticals

We have updated our Rayno Biopharmaceuticals Portfolio with total returns from inception 3/9/09 to 3/30/12.

  • Biggest winners are Alexion (ALXN) Biogen (BIIB) , Cubist (CBST), Regeneron (REGN) and Viropharma (VPHM)-all over 200%. Over the same period the IBB ETF was up 75%.
  • Losers were Albany Molecular (AMRI) down 40% and Gilead (GILD) down 4%.
  • The ten year high for the IBB was this quarter at $124.66. The biotech bull market is intact but hedging should be considered or some profits taken.
  • Over 3 Years the Fidelity Biotechnology Fund (FBIOX) is up 20.76% annualized.
  • Biopharmaceutical stocks have outperformed tools and diagnostic stocks.We will review our Diagnostics/Tools Portfolio next week.

For more details see our Guide to Biotechnology Investing as published in Investor Uprising on May 27, 2011.

2012 Price Original P Price % Ret Price Price % Ret
Summary 7/2/10 Recomm Dec’10 2010 4/4/11 3/30/12 Tot
Alexion ALXN 50.45 2/2/09 35 80.55 130 100.79 92.86 530 split
Albany Molec AMRI 2/10/11 4.68 added 4.32 2.78 -40
Astex ASTX trade 12/27/11 1.63 1.86 14
Amgen AMGN 51.7 2/2/09 55 54.9 0 54 67.8 24
Biogen BIIB 49.42 2/2/09 48.5 67.05 37 73.25 126.41 260
Cephalon CEPH 55.95 2/2/09 76.5 61.72 -19 76.92 80.18 30 acquired
Cubist CBST 20.7 2/2/09 21.5 21.4 -3 28.35 43.51 200
Dendreon DNDN trade 11/15/11 8 10.52 37++
Exelixis EXEL trade 9/2/10 3.3 8.21 148 11.12 5.2 57++
First Trust ETF FBT 30.4 4/15/10 37.5 39.11 3 41.3 42.18 13 use IBB
Gilead GILD 34.9 2/2/09 51 36.24 -29 42.81 48.8 -4
iShares ETF IBB 76.6 2/2/09 70.5 93.42 32 101.14 123.58 75
Micromet MITI 6.28 2/2/09 4 8.12 103 5.46 10.91 272 acquired
ImmunoGen IMGN New 12/22/11 12.4 13.9 12
Optimer OPTR 2/18/11 11.8 added 13.8 13.94 18
Regeneron REGN 21.6 2/2/09 17.5 32.83 82 45.43 116.44 662
Seattle Gen. SGEN 11.85 2/2/09 9.5 14.95 57 15.72 20.48 215
ViroPharma VPHM 10.88 2/2/09 12 17.32 44 20.05 30.1 251

Pin It on Pinterest